Small cell lung cancer enters the era of precision medicine

In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new ``inflamed'' subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.

Automated summary

Gay et al. present a molecular classification of small cell lung cancers in Cancer Cell, extending previous studies on personalized treatments. Their identification of an "inflamed" subtype suggests potential susceptibility to immunotherapy after acquired chemoresistance.